Long-term disease-free survival in three ovarian cancer patients with a single relapse

Recurrent ovarian cancer with long-term survival is uncommon and often associated with poor prognosis. We report three cases of patients with advanced ovarian cancer who have achieved long-term disease-free survival following a single prior relapse. Case 1 relapsed with a localized bulky tumor and received a complete surgical resection and chemotherapy. Case 2 had a persistent central pelvic tumor after debulking surgery and second-line chemotherapy, and yet achieved excellent control with concurrent chemoradiation to the true pelvis. Case 3 relapsed with paraaortic lymph node metastasis and probable lung metastasis (subsequently negated by positron emission tomography) and received chemotherapy alone. These three patients have since remained disease-free for 13, 12, and seven years, respectively, since their first relapse. We conclude that select patients can obtain long-term disease-free survival after the first relapse by accurate restaging and aggressive multimodality treatment.

Disease-free survival; Ovarian neoplasm; Recurrence; Treatment outcome

[1] Parkin D.M., Bray F., Ferlay J., Pisani P.: “Global Cancer Statistics, 2002.” CA Cancer J. Clin., 2005, 55, 74.

[2] Cancer Registry Annual Report, 2008 Taiwan: Department of Health, Executive Yuan, 2010.

[3] Cannistra S.A.: “Cancer of the ovary.” N. Engl. J. Med., 2004, 351, 2519.

[4] Armstrong D.K.: “Relapsed ovarian cancer: challenges and management strategies for a chronic disease”. Oncologist, 2002, 7 (suppl. 5), 20.

[5] Parmar M., Ledermann J., Colombo N., Bois Ad, Delaloye J., Kristensen G. et al: “Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial”. Lancet, 2003, 361, 2099.

[6] Sher-Ahmed A., Buscema J., Sardi A.: “A case report of recurrent epithelial ovarian cancer metastatic to the sternum, diaphragm, costae, and bowel managed by aggressive secondary cytoreductive surgery without postoperative chemotherapy”. Gynecol. Oncol., 2002, 86, 91.

[7] Micha J.P., Goldstein B.H., Hunter J.V., Rettenmaier M.A., Brown J.V.: “Long-term survival in an ovarian cancer patient with brain metastases”. Gynecol. Oncol., 2004, 92, 978.

[8] Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J. et al.: “Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma”. Cancer, 2006, 106, 1933.

[9] Sebastian S., Lee S.I., Horowitz N.S., Scott J.A., Fischman A.J., Simeone J.F. et al: “PET-CT vs CT alone in ovarian cancer recurrence”. Abdom. Imaging, 2008, 33, 112.

[10] Fulham M.J., Carter J., Baldey A., Hicks R.J., Ramshaw J.E., Gibson M.: “The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project”. Gynecol. Oncol., 2009, 112, 462.

[11] Albuquerquea K.V., Singlaa R., Potkulb R.K., Smithb D.M., Creecha S., Loa S. et al: “Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer”. Gynecol. Oncol., 2005, 96, 701.